Idera Pharmaceuticals, Vivelix Pharmaceuticals, Ltd. Enter Into Exclusive License Agreement for the Worldwide Rights to IMO-9200; Idera To Receive Upfront Fee Of $15M And Eligible For Future Payments Up To $140M
Paul Quintaro